JS001: Clinical Trials

17 trials of JS001, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 unknown, 3 completed, 2 recruiting, 1 active not recruiting. 17 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 117Unknown 8, Completed 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 26Unknown 4, Not yet recruiting 1, Terminated 1

Follow JS001: new trials by email Literature Review of JS001 trials Research Report on JS001

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 1RecruitingMetaclipse Therapeutics Corporation302026-10-012026-10-27
Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
Propranolol Hydrochloride, Toripalimab, Chemotherapy - Resectable Non-Small-Cell Lung Cancer
Phase 1RecruitingSecond Xiangya Hospital of Central South University92026-06-012026-10-21
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
JS001, JS004, JS007 - Pancreatic Cancer
Phase 1 / Phase 2Not yet recruitingFudan University1172024-04-302024-04-17
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RC118, Toripalimab, RC148 - Advanced Solid Tumor
Phase 1 / Phase 2UnknownRemeGen Co., Ltd.482023-08-032025-01-29
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
KD6001, Toripalimab - Melanoma
Phase 1 / Phase 2UnknownShanghai Kanda Biotechnology Co., Ltd.842023-03-222023-04-27
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Neo-T, Toripalimab, Tislelizumab - Solid Tumor
Phase 1UnknownBGI, China62023-01-102023-07-10
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
TAB006, Toripalimab - Previously Treated, Advanced, Malignancies
Phase 1WithdrawnShanghai Junshi Bioscience Co., Ltd.2022-03-152022-05-31
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
ES102, JS001 - Solid Tumor, Neoplasms
Phase 1CompletedElpiscience Biopharma, Ltd.302021-10-152025-06-23
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
Toripalimab, Anlotinib, SBRT 7Gy✖️5 QD - NSCLC
Phase 1CompletedHubei Cancer Hospital132021-10-012025-02-07
Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
Donafenib Tosilate Tablets, Toripalimab Injection - Unresectable Hepatocellular Carcinoma
Phase 1UnknownSuzhou Zelgen Biopharmaceuticals Co.,Ltd182021-01-082024-03-06
Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
Donafenib Tosilate Tablets, Toripalimab Injection - Advanced Hepatocellular Carcinoma
Phase 1 / Phase 2UnknownSuzhou Zelgen Biopharmaceuticals Co.,Ltd462020-10-152022-11-29
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
Atezolizumab, Avelumab, Cemiplimab - Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
Phase 1Active not recruitingUniversity of Southern California102020-08-122026-09-21
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
APG-1387 for Injection, Toripalimab - Advanced Solid Tumor
Phase 1 / Phase 2TerminatedAscentage Pharma Group Inc.402020-04-102026-01-08
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TAB004, Toripalimab - Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Phase 1UnknownTopAlliance Biosciences4992019-10-302024-02-05
JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
JS001, regorafenib tablet - Colorectal Cancer
Phase 1 / Phase 2UnknownSun Yat-sen University442019-03-122020-05-12
Study of JS001 in Patients With Advanced Neuroendocrine Tumors
humanized anti-PD-1 monoclonal antibody - Neuroendocrine Tumors
Phase 1CompletedPeking University402017-04-062019-06-21
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
JS001 - Lymphoma, Lung Cancer
Phase 1UnknownShanghai Junshi Bioscience Co., Ltd.332016-08-012019-10-22

Conditions studied

Carcinoma, Non-Small-Cell Lung (3)  ·  Melanoma (3)  ·  Lymphoma (2)  ·  Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Hypopharyngeal Neoplasms (1)  ·  Laryngeal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Mouth Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasm Recurrence, Local (1)  ·  Neuroendocrine Tumors (1)  ·  Oropharyngeal Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

Shanghai Junshi Bioscience Co., Ltd. (2)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2)  ·  Ascentage Pharma Group Inc. (1)  ·  BGI, China (1)  ·  Elpiscience Biopharma, Ltd. (1)  ·  Fudan University (1)  ·  Hubei Cancer Hospital (1)  ·  Metaclipse Therapeutics Corporation (1)  ·  Peking University (1)  ·  RemeGen Co., Ltd. (1)  ·  Second Xiangya Hospital of Central South University (1)  ·  Shanghai Kanda Biotechnology Co., Ltd. (1)  ·  Sun Yat-sen University (1)  ·  TopAlliance Biosciences (1)  ·  University of Southern California (1)

Countries

China (13)  ·  United States (3)

Top investigators

Sheng Yao, PhD (2)  ·  Christopher Pack, PhD (1)  ·  Gino K In, MD (1)  ·  Jian Zhang, Doctor (1)  ·  Kristen Jacobsen, PhD (1)  ·  Lin Shen, MD, PhD (1)  ·  Michael Coleman, PhD (1)  ·  Periasamy Selvaraj, PhD (1)  ·  Qing Xu, Doctor (1)  ·  Rui-hua Xu, PhD (1)  ·  Shanzhi Gu, MD (1)  ·  Shukui Qin, PhD (1)  ·  Tianshu Liu, ph.D (1)  ·  Yifan Zhai, M.D., Ph.D. (1)  ·  Yong Chen, Doctor (1)

Results publications

PMID 25213161, PMID 25981818, PMID 26755520, PMID 30522017, PMID 30642373, PMID 32086343, PMID 32224416

NIH funding

P30CA014089 (1)